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Abstract
Background: People living with HIV/AIDS (PLWA) often use African Traditional Medicines (ATM) either alone or in combi-
nation with Western medicines including Antiretrovirals (ARV).
Objective: To explore the prevalence of  concurrent Antiretrovirals (ARV) and African Traditional medicines (ATM) use and 
determine the effects of  any concurrent use on the CD4+ Lymphocyte count and Viral Load (VL) of  PLWA in the eThekwini 
Metropolitan area.
Methods: A descriptive and exploratory study was carried out on 360 patients. Information was gathered on patients socio-
economic characteristics, ATM usage, outcome measures of  HIV disease progression (CD4+ Count, VL). The data was analysed 
using descriptive statistics, univariate and multivariate analyses.
Results: 4.98% (14/281) of  the patients used ATM and ARV concurrently during the study period. Over 65% (185/281) re-
ported ATM use before diagnosis with HIV whilst 77.6% (218/281) reported previous ATM use after their HIV diagnosis but 
before initiation with ARV. Place of  residence (p=0.004), age (p<0.001) and education level (P=0.041) were found to be signifi-
cantly and positively correlated with ATM use. There were no statistically significant changes in mean plasma CD4+ Count and 
inconclusive effects on VL during the period of  the study in the group taking ARV alone when compared with the group using 
ARV and ATM concomitantly.
Conclusion:  Concurrent ARV and ATM use is quite low (4.98%) when compared to ATM use before HIV diagnosis and after 
HIV diagnosis but before initiation with ARV. This may point to efficient pre-counselling efforts before ARV initiation by health 
care professionals. This study also demonstrated that there were no significant differences in the CD4+ and inconclusive effects 
on VL, between patients taking both ARV and ATM concomitantly and those using ARV alone.
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Introduction
Human immunodeficiency Virus and Acquired Im-
mune deficiency Syndrome (HIV/AIDS) has grown to 
pandemic proportions and has become a major health 
problem Worldwide. Approximately 36.9 million people 
Worldwide are living with HIV and since 2000 around 
25.3 million people have died as a result of  AIDS related 
illnesses1. According to the 2014 Joint United Nations 
Programme on HIV and AIDS (UNAIDS ) update, sixty-
nine percent of  people infected with the HIV live in Sub-
Saharan Africa1. South Africa has an estimated 6.8 mil-
lion people living with HIV and this represents the largest 
number of  people living with HIV in any countryMS41. 
HIV/AIDS has worsened the demands on the health care 
system in Africa and has put an already overburdened sys-
tem under further strain1. Antiretroviral therapy (ART) 
using antiretroviral drugs(ARV) is the only proven man-
agementMS5  of  HIV-infection and has led to reduction 
in HIV related opportunistic infections and AIDS related 
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deaths, and have thus improved substantially the quality 
of  life in People living with HIV/AIDS (PLWA)2.
It is estimated that there are approximately 200,000 Afri-
can traditional healers in South Africa and that between 
70 and 80 per cent of  South Africans use the services 
of  Traditional Health Practitioners (THP)3.  South Africa 
like many developing countries has a pluralistic healthcare 
system wherein a modernised first world medical system 
co-exists with a variety of  non-conventional health care 
systems such as local indigenous systems founded on tra-
ditional beliefs and practices4.
In South Africa, the use of  modern medicines has never 
fully replaced the indigenous system, and THPs continue 
to be consulted by the black population including PLWA 
for a variety of  reasons3. The commonly treated illnesses 
including nausea and vomiting, lack of  energy, lack of  ap-
petite, skin disorders, weight loss and diarrhea. Tradition-
al Medicine (TM) is also used to treat the side effects of  
ARV drugs as well as fungal infections, dizziness, stom-
ach upsets and pain5. Other reasons for TM use in PLWA 
is to supplement dietary intake, boost energy levels and 
improve immune response as well as a misguided belief  
that some TM can cure HIV/AIDS6. African traditional 
medicines (ATM) are regarded as a credible and conve-
nient source of  health care and dual treatment regularly 
takes place as a result4. THP thus have a crucial role to 
play in building the health system of  South Africa includ-
ing the management of  PLWA5.
During the peak of  the HIV/AIDS pandemic in the late 
1990’s before the era of  massive ARV roll-out programs, 
when ARVs were largely unaffordable and inaccessible, 
ATM were the mainstay of  HIV management amongst 
PLWA in Africa5. The advent of  ARV rollout programs 
did not substitute ATM use amongst the population3 
and many studies attest to this. In Uganda for example, a 
2007 study showed that 63.5 % of  PLWA had used TM 
after HIV diagnosis and same-day, concomitant ATM 
and ARV use was reported by 32.8% of  the patients sur-
veyed7. In a tertiary hospital in Kano, NorthWest Nige-
ria, it was found that 4.25% of  the 430 patients surveyed 
used ARV and traditional medicine concomitantly8.  A 
survey of  67 PLWA done at three ART centres in the Ku-
masi Metropolis in Ghana found that concomitant TM 
and ARV use was reported by 53.2% of  the patients9. 
An astounding 98.2% of  388 patients interviewed  at the 
Family Care Centre (FCC) ART clinic in Harare, Zimba-
bwe were found to be using at least one ATM concur-
rently with their ARV medication10.
A cross-sectional survey done in 2007 among PLWA at-
tending a workplace ART clinic in South Africa found 
that 23% used ATM concurrently with their ATM6. A 
2012 cross-sectional study which involved 100 partici-
pants enrolled at ARV clinics in two South African prov-
inces showed that less than 20% of  participants used TM 
and ARV simultaneously11. However, close to 80% of  
participants utilised TM before contracting HIV, which 
is in keeping with approximate estimates by the WHO12. 
According to Malangu, 7.7% PLWA on ART in Pretoria, 
South Africa, concurrently used traditional health, care 
and over-the-counter medicines13.
Although the use of  Traditional Medicines (TM) is wide-
spread, their use is not well researched, and consequently 
poorly regulated4. Limited meta-analyses of  safety and 
efficacy exist and low-level evidence of  harm identifies 
the potential for herb-drug interactions (HDI) with many 
medicines including the commonly used ARV14.
The potential HDI may occur in similar fashion to the 
typical Drug-Drug interactions (DDI) at any of  the stag-
es of  absorption, distribution, metabolism  and excretion 
(ADME) phases of  the pharmaceutical disposition of  the 
drug in the human body affecting the entire pharmaco-
kinetic profile of  the drug15. Herb-induced inhibition or 
induction of  the cytochrome enzymes can alter the me-
tabolism of  ARVs, leading to adverse effects or lack of  
efficacy15.The concomitant intake of  TM in patients us-
ing ARVs may result in lowering of  plasma drug concen-
trations resulting in treatment failure, drug resistance and 
possibly death of  the patient15. Alternatively, concomitant 
intake may also result in increased plasma drug concen-
trations resulting in drug toxicity15.
Mills et al. in 2005 showed that extracts of  African potato 
(Hypoxis hemerocallidea) had significant effects on cyto-
chrome P450 3A4 in-vitro metabolism and so potentially 
could result in sub-therapeutic plasma concentrations16. 
A 2014 laboratory study of  the inhibition of  major drug 
metabolising enzymes by Hypoxis hemerocallidea(H. 
hemerocallidea), Echinacea purpurea (E. purpurea), 
Moringa oleifera (M. oleifera),  Taraxacum officinale (T. 
officinale) and Lessertia frutescens (L. frutescens) dem-
onstrated that TM have the potential to interact with 
ARV17. Conversely, a 2013 study on adult volunteers, by 
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Gwaza et al. showed that Hypoxiswhen taken concur-
rently with lopinavir/ritonavir(LPV/r)is well-tolerated 
and is not associated with clinically significant changes in 
LPV/r pharmacokinetics18.  International guidelines for 
the management of  HIV/AIDS recommend the use of  
plasma viral load (VL) measurements as the key tool in 
predicting HIV viral suppression and treatment success 
for patients on ART19. In resource limited settings which 
have inadequate access for VL measurements, treatment 
outcomes in PLWA on ART are measured using other 
clinical tools such as CD4+ T-cell (CD4) count, changes 
in the patient’s Body Mass Index (BMI) as well as the 
presence or absence of  opportunistic diseases20. Not-
withstanding the laboratory studies mentioned above and 
others, and the known,albeit usually sub-clinical DDI in 
the components of  most ART regimens, there remains 
no definitive position by most policy makers on the effect 
of  individual ATM on the effects of  concurrent use of  
ART and ATM on VL and CD4+ counts amongst PLWA 
due to the absence of  a large randomised control trials.
Aim and objectives:
Objective of  the study was to explore the occurrence of  
concurrent ART and ATM use amongst PLWA in the 
eThekwini Metropolitan area with the following aims: to 
determine the socio-demographic profiles of  the respon-
dents, the types of  ATM used and the reasons for their 
use of  ATM with ARV as well as to determine  the effects 
of  any concurrent use on the CD4+ Lymphocyte count 
and Viral Load (VL) of  such patients.
Ethical considerations
Ethical clearance for the study was obtained from Uni-
versity of  KwaZulu-Natal Biomedical Research Ethics 
Committee (BREC REF: BE272/14), the KwaZulu-Na-
tal health Research Committee (REF: HRKM240/14) in 
the provincial Department of  Health as well as permis-
sion from the CEO’s of  the four health institutions be-
fore data collection commenced.
Methods
Design, setting and study population
The study was conducted in two phases. The first phase 
was a cross sectional descriptive study aimed at collecting 
information on patient demographics and ATM use as 
well as to recruit participants for the second phase of  the 
study. The second phase was a longitudinal study which 
involved data collection from the patient’s charts using a 
case report form.  The study was carried out in the region 
of  the eThekwini Metropolitan area. The eThekwini met-
ro is a mostly urban area consisting of  approximately 3.5 
million people and is located in the east coast of  the Re-
public of  South Africa (RSA)21. The population is com-
prised mostly of  black African (73.8%), followed by Indi-
an/Asian (16.7%), White (6.6%) and coloureds (2.5%)21. 
The population is serviced with sixteen provincial hos-
pitals and eight community health centres22.  This study 
was conducted at four public health facilities that supply 
ARV treatment in the eThekwini Metropolitan (Metro) 
area. These facilities were randomly selected from a list 
supplied by the provincial department of  health of  facili-
ties that supply ARV treatment in the metro. A minimum 
sample size of  360 HIV-infected, treatment experienced 
adults (≥18 years old) was determined to be a suitable 
number in order to cater for any ‘loss to follow up’ pa-
tients. Every second patient attended to at the health fa-
cility was approached with the study information leaflet 
to participate in the study. After obtaining their consent 
,patients were recruited continuously until the desired 
sample size of  360 participants who met the inclusion 
criteria was achieved. Only patients who had been sta-
bilised on the same fixed dose first-line ART regimen 
which consists of  tenofovir (TDF), emtricibatine (FTC) 
and efavirenz (EFV) for the past 6 months were consid-
ered for the study. Patientsof  the FDC were preferred 
by the researcher as this is the most commonly used first 
line regimen according to current treatment guidelines23.
Furthermore, patients on the FDC were deemed to be 
more likely to be compliant to treatment and so negate 
non-adherence as a confounder to treatment failure23. 
Instrument, data collection, capture and analysis
An anonymous coded questionnaire was administered to 
each of  the selected 360 participants. The variables gath-
ered included characteristics such as age, gender,ethnicity, 
level of  education and place of  residence. Other variables 
collected include current ARV regimen, previous and 
current ATM use, names and routes of  administration 
of  ATM used, reason for ATM use and awareness of  any 
dangers in concurrent ATM and ARV use. Based on re-
sponses from this phase, patients were divided into two 
cohorts; users of  ARV alone (-ATM) or users of  both 
ARV and ATM (+ATM).
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Subsequent to the collection of  the above mentioned pa-
tient data, a second phase of  the study was initiated. This 
was a longitudinal study which involved data collection 
of  patient clinical information from the patient’s charts 
using a Case Report Form (CRF). The data was collected 
both retrospectively (6 months) and prospectively (over 
12 months, in six month intervals). Clinical data collected 
included CD4+ lymphocyte counts, patient Viral load 
(VL), treatment failure, presence of  Adverse Drug Reac-
tions (ADR) and Opportunistic infections (OI) as well as 
any documented ATM use if  available.
The data was then captured and analysed using Statistical 
Package for the Social Sciences Package for Windows® 
by IBM (IBM SPSS®) version 21. [MS19] Results were 
expressed in terms of  frequency, mean values and Stan-
dard Deviations (SD). Frequencies and proportions (%) 
were calculated to describe categorical variables such as 
age, gender, place of  residence, level of  education and 
ATM use. Results from open ended questions were cap-
tured using IBM SPSS ®. Categories were developed and 
responses were sorted and tabulated according to labelled 
categories to allow for sorting and counting of  responses.
Average CD4+ and VL for both cohorts at Time 0 (6 
month retrospective), Time 1 (Baseline), Time 2 (6 month 
prospective) and Time 3 (12 month prospective) were de-
termined. In the event of  the patient charts having missing 
clinical information (one or more missing CD4+ and/or 
VL measurements), the average[MS20]  of  the available 
readings would be used in the place of  the missing data.
The association between the Health outcomes (Average 
CD4+ counts and VL) and use of  ATM were examined 
using a standard t-test for independent means. A statisti-
cian was consulted to verify the statistical analysis.
Results
Excluded participants.
Out of  the subset of  360 patients who met the inclu-
sion criteria and so chosen to participate in this study, 79 
patients were excluded due to ‘loss to follow-up’ either 
through death (4 patients) or through completely unus-
able clinical information in the patient charts (absent 
CD4+ or VL).
Socio-demographic characteristics
Out of  the remaining 281 patients surveyed, 69.9%were 
females and almost all (96.8%) were of  African (black) 
ethnicity. The mean age of  the participants was 39 (with 
a range from 19 to 69 years). The majority of  the par-
ticipants were relatively under-educated with only 6.7% 
having obtained a tertiary qualification and most (48.4) 
only having a primary education. It was also found that 
the majority of  the patients (64.4%) resided in an urban 
township.
The sample size population characteristics are depicted 
in figure 1;
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Figure 1: Sample Size Population Characteristics 
Demographics and ATM use
The majority (71.4%) of  concurrent ATM and ARV 
(+ATM) users were Africans (black) above the age of  40 
and resided in urban townships (57.1%). Most of  the pa-
tients (85.7%) who took ATM concurrently with ARV 
had primary education or lower qualification. Sixty three 
(22.4%) patients reported to never have used ATM.
Table 1 shows summary demographic characteristics of  
patients surveyed, stratified by ARV users only or ARV 
and ATM users.
Table 1: Demographic characteristics of patients surveyed (N=281) 
 
Patient Characteristic ARV users only 
(%) 
ARV and ATM 
users (%) 
Total [n (%)] 
Age 
18-25 96.3 3.7 27 (9.6) 
25-35 97.2 2.8 72 (25.6) 
30-35 98.1 1.9 53 (18.9) 
40-45 95.3 4.7 43 (15.3) 
45-50 92.3 7.7 52 (18.5) 
>50 88.2 11.8 34 (12.1) 
Gender 
Male 90.8 9.2 87 (30.1) 
Female 96.9 3.1 194 (69.9) 
Ethnic Group 
Black 94.9 5.1 272 (96.8) 
White 0 0 0 
Indian 100 0 3 (1.1) 
Coloured 100 0 6 (2.1) 
Other 0 0 0 
Level of  Education 
No Education 94.2 5.8 69 (24.6) 
PrimaryEducation 94.1 6.9 136 (48.4) 
Secondary Education 96.5 3.5 57 (20.3) 
Tertiary Education 100 0 19 (6.7) 
Place of Residence 
Urban Suburban 98.3 1.7 58 (20.6) 
Urban Township 95.6 4.4 181 (64.4) 
Peri-Urban 90 10 30 (10.7) 
Rural 83.3 16.7 12 (4.3) 
14 out of  the 281 (4.98%) patients reported concurrent 
use of  ATM with ARV(+ATM) during the study period. 
Of  the total patients surveyed. 65.8% reported ATM use 
before diagnosis with HIV whilst 77.6% reported previ-
ous ATM use after their HIVdiagnosis (but before initia-
tion with ARV). This is shown in Fig. 2;
African Health Sciences Vol 16 Issue 4, December, 2016  1122
None of  the patients in the +ATM cohort had a tertiary 
qualification and all were of  African ethnicity. Univari-
ate analysis for predicting ATM use was significantly as 
well as positively correlated with gender (p<0.001), age 
(p=0.032) education level (p<0.001) as well as place of  
residence (p=0.032). Multivariate analysis, obtained from 
combining all independent and controlling factors, for 
predicting ATM use resulted in education level (p<0.041), 
place of  residence (p=0.004) and age (p<0.001).
 
Further details are elucidated in Table 2
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ATM use before HIV diagnosis ATM use after HIV diagnosis but 
prior to ARV initiation
Concurrent ATM and ARV use 
ATM use amongst PLWA
Table 2: Statistical association of independent variables to predict ATM use 
 
Patient Characteristic % Concurrent ARV 
and ATM use 
Univariate p 
value 
multivariate p value 
Age 









Male 57.14 <0.001  <0.018 
Female 42.86 
Ethnic Group 
Black 100 <0.001  <0.001 
Level of  Education 
No Education 28.57 <0.001  <0.041 
Primary Education 57.14 
Secondary Education 14.29 
Place of Residence 
Urban Suburban 7.14 0.032  0.004 




Types of  ATM
The most commonly used ATM amongst the +ATM 
group was the African potato (H. hemerocallidea); used in 
its crude form or commercial preparations such as Ink-
omfe capsules or Moducare®) which was used by 9 pa-
tients (64.3%). This was followed by Sutherlandia at 21.4%. 
Two of  the +ATM patients routinely used Stametta™ (a 
commercially prepared mixture of  herbs including Aloe, 
aniseed oil and other nutrients which is sold Over-the-
counter in pharmacies and health shops and is purported 
to ‘strengthen the immune system and improve general 
well-being) and ubhejani (a traditional concoction of  un-
known composition sold in muthi markets in downtown 
Durban and townships). The average time for utilisation 
of  ATM for the patients who took ARV and ATM con-
currently was 4.3 months. In response to whether or not 
they had informed their medical doctor of  their concur-
rent ATM use, all 14 patients (100%) responded nega-
tively and indicated that their doctors were not aware of  
their concurrent use of  ATM.
Reasons for ATM use
77.5 (218/281) of  the patients claimed to have previously 
or currently used ATM and cited one or more reasons for 
using ATM.  Reasons for using ATM included to boost 
immunity (68%), increasing appetite (61%), tonic for fa-
tigue (55%), treating stomach pains/diarrhea (27%), al-
leviating fever (21%), treating joint pains (13%), treating 
headaches (11%), treating ARV side effects (7%) and el-
evating mood (4%). This is depicted in the table below 3;
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Table 3: Utilisation of ATM (n=218) 
 
Indication Percentage (%) 
(n=218) 
Immune Supplementation 68 
Increasing Appetite 61 
Tonic 55 
Abdominal symptoms (Stomach pain/diarrhea) 23 
Fever 21 
Joint Pain 13 
Headache 11 
Treating ARV symptoms 7 
Elevating mood 4 
No particular reason 2 
 
91% (256/281) of  the patients cited knowledge of  the 
potential interactions between ATM and ARV and men-
tioned that the health care provider had underscored the 
potential dangers of  simultaneous ARV and ATM use to 
them during pre-counselling before initiation of  ART.
Clinical information
Effect on CD4
The majority (72%) indicated living with HIV for at least 
3 years. As per the inclusion criteria, all patients surveyed 
were on the FDC drug, or its singular components (Teno-
fovir + Emtricitabine/3TC + Efavirenz) for a minimum 
period of  6 months. Based on the commencement of  
current ARV regimen, it was found that average period 
of  use of  the FDC combination drug at the time of  first 
contact with the patients was 9.3 months. Information on 
previous ARV regimens was scanty and so was excluded 
from the study. The mean CD4+ values for the study pe-
riod are represented in Table 4;
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Table 4: CD4+ counts 
 









































The mean baseline CD4+ count in the ATM cohort 
was 501 cells/mm3. There was a 9.2% increase in CD4+ 
counts in the –ATM group compared to the base line 
values after the 12 month prospective measurements 
subsequent to the 3.6% increase in CD4+ count at the 6 
month interval. In comparison, the CD4+ counts in the 
+ATM cohort responded similarly to the –ATM group 
with incremental increases in mean CD4+ count of  6.0% 
and 9.5% at 6 month and 12 month interval respectively. 
The differences between the two means in the –ATM and 
+ATM groups at each CD4+ cell count measure were 
not significant at 5% level for Time 0 (p=0.18), Time 2 
(p=0.26) and Time 3 (p=0.09).
Effect on VL
The mean viral loads (VL) for the patients during the 
study period are recorded in Table 5. 
Table 5: Viral Load (VL) measurements 
 









































At baseline, the VL in the -ATM group ranged from 
undetectable to 79120 copies/mL with an average of  
12855 copies/mL. The +ATM group had a mean VL of  
11677 copies/mL ranging from undetectable to 25435. 
The VL in the –ATM group reduced by 31.35% and 35% 
compared to the baseline VL in Time 2 and Time 3 re-
spectively.  The differences between the two means in 
the –ATM and +ATM groups is significant at 5% level 
for Time 0(p=0.013), marginally significant at Time 1 
(p=0.048), Significant at Time 2 (p=0.040) and not sig-
nificant at Time 3 (p=0.069).
Discussion
Overall, 65.8% (185/281) of  the patients had used ATM 
before HIV diagnosis and 77.6% (218/281) after diag-
nosis. This indicated a health seeking approach by the 
respondents through their ATM practitioners after ini-
tial HIV diagnosis. These figures are in line with World 
Health Organization (WHO) estimates of  about 80% 
Worldwide ATM usage and even closer to a South Afri-
can estimates of  around 70%5,12. 
A majority of  the patients surveyed (95.02%) did not 
use ATM concurrently with ARV. With the paucity of  
data on the concurrent use of  ATM and ARV, and the 
fact that in-vitro studies indicate possible interactions be-
tween commonly used ATM and ARV15, this finding can 
be viewed in a positive light. However, 4.98% (14/281) 
patients did report the concurrent use of  ATM with 
ARV during the study period. The frequency of  concur-
rent ATM use iscomparable with similar studies in urban 
centres in Pretoria, South Africa13 as well as Kano, Nige-
ria8  which had 4.40% and 4.3% incidence rate of  concur-
rent ATM and ARV use respectively. This study differed 
vastly with a 2004 Uganda study by Langlois-Klassen et 
al7 which reported a rate of  32.8% for concurrent ARV 
and ATM use7. The comparison of  the results obtained 
in the current and other similar studies is better compare 
using Table 6.
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The differences between the current study and the 
Karabole could be attributed to different cultural and 
socio-economic factors. The current study was done in 
an urban metro in South Africa and the Karabole study 
in a rural setting in Western Uganda. The researcher pos-
tulates that the lower rate of  ATM usage could be due 
to better access to ART services, as is usually the case 
in an urban setting, and the fact that the Karabole study 
was carried out in 2004 before the extensive ART roll-out 
programmes initiated by most governments.
It is important to note that a 2008 study by Peltzer and 
Mnqundaniso in the same setting as the current study (ur-
ban eThekwini), found an incidence rate of  44.4% for 
simultaneous ARV and ATM use5.  It could be surmised 
that even greater access to ARV through universal ac-
cess programs since 2008 and the reduced costs of  these 
treatments would have resulted in a reduced demand for 
ATM6. Furthermore, there was growing evidence of  in-
vitro studies which indicated that commonly used South 
African ATM interacted with ARV15,16,17.
Reduced ATM use in the current study may also be at-
tributed to efforts by health care professionals in commu-
nication the potential for herb-drug interactions (HDI) 
to patients during pre-counselling sessions. This study 
showed that 91% of  the patients cited a knowledge of  
these potential HDI and that the health care provider had 
underscored the potential dangers of  simultaneous ARV 
and ATM use to them during pre-counselling before initi-
Table 6: Comparison of ATM usage in PLWA 
 
 























Period of study Current study 2008 2004-2005 2014 2004 
Setting Urban Urban Urban Urban Rural 
Concurrent ATM 
and ARV use 
4.98% 44.4% 4.40% 4.30% 32.80% 
ATM use after HIV 
diagnosis (before 
initiation of ARV) 
77.60% -  -  20.90% 63.50% 
ATM use before 
HIV diagnosis 
65.80% - - 27.50% 90.40% 
ation of  ART. This is further reiterated by the vast differ-
ences in ATM before HIV diagnosis, after HIV diagnosis 
and after initiation of  ARV therapy (65.8%, 77.6% and 
4.98% respectively).
The majority of  the participants were relatively under-
educated with only 6.7% having obtained a tertiary quali-
fication and most (48.4%) only having a primary educa-
tion. It was also found that the majority of  the patients 
(64.4%) resided in an urban township. This unfortunately 
mirrors the epidemiology of  HIV/AIDS in South Af-
rica which largely affects the uneducated, females and 
persons of  low income4. Multivariate analysis, obtained 
from combining all independent and controlling factors, 
for predicting ATM use showed that level of  education 
level (p<0.041), place of  residence (p=0.004) and age 
(p<0.001) is associated with concomitant ARV and ATM 
use.
The ATM used where African potato, Sutherlandia, Stamet-
ta and unspecified traditional mixtures (including ubhe-
jani). This showed a similar trend to the 2004, Pretoria 
study by Malangu which highlighted commonly used 
ATM as African potato, coconut as well as unspecified 
crude herbal mixtures7.
Concomitant use of  ATM is generally discouraged during 
ARV treatment and so there is a chance of  under report-
ing of  the use of  ATM use by the participants. This is ex-
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pected in subjective measurements due to the perceived 
possibility of  punitive consequences from the health-
care-provider by the participant if  he/she admits to the 
use of  ATM.  This could also explain the finding that in 
all cases, patients who used ATM concurrently with ARV 
did not communicate their ATM use to their health care 
provider. This could also further indicate that patients are 
aware of  the potential risks of  concomitant use, but how-
ever, continue to do so in their attempt to self-medicate.
During the duration of  the study, there was a steady in-
crease in CD4+ counts in the cohort taking ARV alone as 
well as the cohort that used ATM and ARV concomitant-
ly. Similarly, there was on average, a decline in VL in both 
cohorts, albeit, at different rates. The differences between 
the two VL means in the –ATM and +ATM groups are 
less than 0.05 and therefore is significant at 5% level for 
Time 0 (p=0.013), and marginally significant at Time 1 
(p=0.048) and significant at Time 2 (p=0.040). Howev-
er, the differences in the VL means are not significant at 
Time 3 (p=0.069). As a result of  the conflicting p values 
across the time lines, it can be concluded that the effect 
of  ATM on ARV is inconclusive.
Overall, statistical analysis found that in general, the ef-
fect of  concomitant ARV and ATM use was not clinically 
significant. This was in concordance with a 2013 study by 
Gwaza et al study on adult volunteers which showed that 
hypoxis is not associated with clinically significant chang-
es in the pharmacokinetics of  the ARV agent, LPV/r 
pharmacokinetics18.
This study, however, differs from in-vitro studies by Mills 
et al. in 2005 who demonstrated the potential of  hypoxis 
to increase metabolism of  some drugs including ARV 
due to its significant effects on cytochrome P450 3A4 
in-vitro metabolism16.   Furthermore, a 2014 laboratory 
study validated the findings of  Mills and showed that H. 
hypoxis, E. purpurea, M. oleifera,T. officinale and L. frutescens 
inhibited major drug metabolising enzymes and had the 
potential to interact with ARV17. 
Limitations
The findings of  this study may not be generalisable to 
PLWA in South Africa due to the fact that the study was 
concentrated in the eThekwini metro. Several multi-centre 
studies in various centres (Urban, Per-urban, Rural) could 
shed more light on the actual prevalence rate of  ATM 
use in PLWA as well as provide more reliable data on 
the effects of  ATM on clinical outcomes of  PLWA. Cau-
tion is therefore urged in generalising findings to other 
districts and provinces in the country. Clinical co-variates 
such as presence of  opportunistic infections, changes in 
weight (BMI) of  the patients and occurrence of  Adverse 
Drug Reactions (ADR) as a result of  ATM during the 
study period could not easily be retrieved from patient 
charts since the data in the patient charts was often dis-
ordered or absent. This information could possibly have 
added value to the study by demonstrating whether or not 
concomitant use of  ATM and ARV may have resulted 
in increased occurrence of  opportunistic infections, de-
terioration in weight of  the participants or increased the 
incidence of  adverse drug reactions in the +ATM cohort.
Additionally, there is a need to explore and understand 
the knowledge, perceptions and attitudes of  the health 
care workers and quantify their possible role, if  any, in the 
continued reduction of  prevalence rates of  concurrent 
ATM and ARV use in PLWA.
The limitations of  this study could form the basis of  fu-
ture studies on this subject.
Conclusion
This study was able to establish the prevalence of  ATM 
use in PLWA as well as other factors which impact on 
ATM use. This study was also able to show that there 
were no significant effects on the CD4+ and inconclusive 
results on the VL of  HIV infected patients in the eThek-
wini Metropolitan area who use ARV and ATM concur-
rently. 
Recommendations
•The use of  population pharmacokinetic approach in or-
der to make the results more generalisable and to better 
establish a link between ARV plasma levels and concur-
rent ATM use on various patient characteristics.
•The development of  a pharmacodynamic model of  the 
data in order to correlate patient characteristics, ARV 
plasma levels, ATM plasma levels with CD4+ and VL 
levels.
•Continued vigilance by health care practitioners in coun-
selling patients to not use ATM and ARV concomitantly.
•The full professionalisation of  THP and the incorpora-
tion of  THP in the management of  HIV/AIDS.
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